Faerch K, Hulmán A, Solomon TP. Heterogeneity of pre-diabetes and type 2 diabetes: implications for prediction, prevention and treatment responsiveness. Curr Diabetes Rev 2016;12:30-41.
Scheen AJ. Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des maladies Métaboliques 2015;9:186-97.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2016 Executive Summary. Endocr Pract 2016;22:84-113.
DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
Bailey CJ, Del Prato S, Eddy D, Zinman B; Global partnership for Effective Diabetes Management. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005;59:1309-16.
Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with newonset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-75.
Scheen AJ. Inertie thérapeutique dans la pratique médicale : causes, conséquences, solutions. Rev Med Liège 2010;65:232-8.
Reach G. Clinical inertia, uncertainty and individualized guidelines. Diabetes Metab 2014;40:241-5.
Scheen AJ, Giet D. Non-observance thérapeutique : causes, conséquences, solutions. Rev Med Liège 2010;65:239-45.
Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther 2014;5:347-54.
World Health Organization (WHO). Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003. http://www.who.int/chp/knowledge/publications/adherencefullreportpdf 2003
Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013;36:1779-88.
Ceriello A, Gallo M, Candido R, et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med 2014;7:129-36.
Scheen AJ. Personalized medicine in type 2 diabetes. Diabetes Res Clin Pract 2016 [submitted].
